Clinical and therapeutic features and prognostic factors of metastatic colorectal cancer over age 80: a retrospective study.


Journal

BMC gastroenterology
ISSN: 1471-230X
Titre abrégé: BMC Gastroenterol
Pays: England
ID NLM: 100968547

Informations de publication

Date de publication:
01 May 2021
Historique:
received: 16 12 2020
accepted: 26 04 2021
entrez: 2 5 2021
pubmed: 3 5 2021
medline: 15 5 2021
Statut: epublish

Résumé

Colorectal cancer (CRC) is one of the most common cancers in the world. The number of elderly patients with CRC increases due to aging of the population. There are few studies that examined chemotherapy and prognostic factors in metastatic colorectal cancer (mCRC) patients aged ≥ 80 years. We assessed the efficacy of chemotherapy and prognostic factors among patients with mCRC aged ≥ 80 years. We retrospectively analyzed clinical and laboratory findings of 987 patients newly diagnosed with CRC at Asahi General Hospital (Chiba, Japan) between January 2012 and December 2016. The Kaplan-Meier method was used for the overall survival (OS) and the log-rank test was used to identify difference between patients. A multivariate Cox proportional hazard regression analysis was performed to determine the hazard ratios and 95% confidence intervals (CIs) of prognostic factors among super-elderly patients. In total, 260 patients were diagnosed with mCRC (super-elderly group: n = 43, aged ≥ 80 years and younger group, n = 217, aged < 80 years). The performance status and nutritional status were worse in the super-elderly group than in the younger group. The OS of super-elderly patients who received chemotherapy was worse than that of younger patients (18.5 vs. 28.8 months; P = 0.052), although the difference was not significant. The OS of patients who received chemotherapy tended to be longer than that of those who did not; however, there were no significant differences in OS in the super-elderly group (18.5 vs. 8.4 months P = 0.33). Multivariate analysis revealed that carcinoembryonic antigen levels ≥ 5 ng/mL (hazard ratio: 2.27; 95% CI 1.09-4.74; P = 0.03) and prognostic nutritional index ≤ 35 (hazard ratio: 8.57; 95% CI 2.63-27.9; P = 0.0003) were independently associated with poor OS in the super-elderly group. Patients with mCRC aged ≥ 80 years had lower OS than younger patients even though they received chemotherapy. Carcinoembryonic antigen and prognostic nutritional index were independent prognostic factors in super-elderly patients with mCRC, but chemotherapy was not. retrospectively registered.

Sections du résumé

BACKGROUND BACKGROUND
Colorectal cancer (CRC) is one of the most common cancers in the world. The number of elderly patients with CRC increases due to aging of the population. There are few studies that examined chemotherapy and prognostic factors in metastatic colorectal cancer (mCRC) patients aged ≥ 80 years. We assessed the efficacy of chemotherapy and prognostic factors among patients with mCRC aged ≥ 80 years.
METHODS METHODS
We retrospectively analyzed clinical and laboratory findings of 987 patients newly diagnosed with CRC at Asahi General Hospital (Chiba, Japan) between January 2012 and December 2016. The Kaplan-Meier method was used for the overall survival (OS) and the log-rank test was used to identify difference between patients. A multivariate Cox proportional hazard regression analysis was performed to determine the hazard ratios and 95% confidence intervals (CIs) of prognostic factors among super-elderly patients.
RESULTS RESULTS
In total, 260 patients were diagnosed with mCRC (super-elderly group: n = 43, aged ≥ 80 years and younger group, n = 217, aged < 80 years). The performance status and nutritional status were worse in the super-elderly group than in the younger group. The OS of super-elderly patients who received chemotherapy was worse than that of younger patients (18.5 vs. 28.8 months; P = 0.052), although the difference was not significant. The OS of patients who received chemotherapy tended to be longer than that of those who did not; however, there were no significant differences in OS in the super-elderly group (18.5 vs. 8.4 months P = 0.33). Multivariate analysis revealed that carcinoembryonic antigen levels ≥ 5 ng/mL (hazard ratio: 2.27; 95% CI 1.09-4.74; P = 0.03) and prognostic nutritional index ≤ 35 (hazard ratio: 8.57; 95% CI 2.63-27.9; P = 0.0003) were independently associated with poor OS in the super-elderly group.
CONCLUSIONS CONCLUSIONS
Patients with mCRC aged ≥ 80 years had lower OS than younger patients even though they received chemotherapy. Carcinoembryonic antigen and prognostic nutritional index were independent prognostic factors in super-elderly patients with mCRC, but chemotherapy was not.
TRIAL REGISTRATION BACKGROUND
retrospectively registered.

Identifiants

pubmed: 33933007
doi: 10.1186/s12876-021-01791-9
pii: 10.1186/s12876-021-01791-9
pmc: PMC8088714
doi:

Types de publication

Clinical Study Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

199

Références

Lancet Oncol. 2013 Oct;14(11):1077-1085
pubmed: 24028813
Ann Oncol. 2017 Aug 01;28(8):1713-1729
pubmed: 28407110
Medicine (Baltimore). 2014 Dec;93(28):e266
pubmed: 25526455
Cancer. 2013 Feb 15;119(4):722-8
pubmed: 22990939
World J Surg. 2011 Mar;35(3):684-92
pubmed: 21181473
Int J Colorectal Dis. 2018 Aug;33(8):1011-1018
pubmed: 29564541
World J Gastroenterol. 2015 Nov 21;21(43):12410-20
pubmed: 26604648
J Cancer Res Ther. 2018;14(Supplement):S79-S84
pubmed: 29578154
Ann Oncol. 2013 Sep;24(9):2354-60
pubmed: 23704193
Oncologist. 2008 Aug;13(8):876-85
pubmed: 18695260
Ann Oncol. 2004 Sep;15(9):1330-8
pubmed: 15319237
Int J Colorectal Dis. 2019 Apr;34(4):681-689
pubmed: 30680451
Am J Clin Oncol. 1982 Dec;5(6):649-55
pubmed: 7165009
CA Cancer J Clin. 2014 Mar-Apr;64(2):104-17
pubmed: 24639052
Cancer Treat Rev. 2006 Feb;32(1):1-8
pubmed: 16337087
Eur J Cancer. 2018 Jul;98:1-9
pubmed: 29807237
Cancer J. 2005 Nov-Dec;11(6):449-60
pubmed: 16393479
Korean J Intern Med. 2018 Nov;33(6):1182-1193
pubmed: 29166760
Int J Cancer. 2010 Jul 15;127(2):367-80
pubmed: 19908233
Clin Colorectal Cancer. 2018 Dec;17(4):e663-e669
pubmed: 30153975
J Clin Oncol. 2006 Sep 1;24(25):4085-91
pubmed: 16943526
Ann Intern Med. 2002 Mar 5;136(5):349-57
pubmed: 11874307
Aging (Albany NY). 2019 Nov 22;11(22):10301-10315
pubmed: 31760384
Colorectal Dis. 2010 Aug;12(8):754-61
pubmed: 19508508
Cancer Med. 2019 Jul;8(7):3379-3388
pubmed: 31069966
Colorectal Dis. 2020 Apr;22(4):362-363
pubmed: 32237106

Auteurs

Hiroyuki Hisada (H)

Department of Gastroenterology, Graduate School of Medicine, the University of Tokyo, 7-3-1 Hongo, Bunkyo-ku, Tokyo, 113-8655, Japan. hisada-hiroyuki326@g.ecc.u-tokyo.ac.jp.
Department of Gastroenterology, Asahi General Hospital, Chiba, Japan. hisada-hiroyuki326@g.ecc.u-tokyo.ac.jp.

Yu Takahashi (Y)

Department of Gastroenterology, Graduate School of Medicine, the University of Tokyo, 7-3-1 Hongo, Bunkyo-ku, Tokyo, 113-8655, Japan.

Manabu Kubota (M)

Department of Gastroenterology, Asahi General Hospital, Chiba, Japan.

Haruhisa Shimura (H)

Department of Gastroenterology, Asahi General Hospital, Chiba, Japan.

Ei Itobayashi (E)

Department of Gastroenterology, Asahi General Hospital, Chiba, Japan.

Kenji Shimura (K)

Department of Gastroenterology, Asahi General Hospital, Chiba, Japan.

Akira Nakamura (A)

Department of Gastroenterology, Asahi General Hospital, Chiba, Japan.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH